The Journal of
Clinical Psychiatry

Schizophrenia/Schizoaffective Disorders

ASCP Corner May 11, 2008

Antipsychotic Polypharmacy, Part 2: Why Use 2 Antipsychotics When 1 Is Not Good Enough?

Christoph U. Correll, MD

J Clin Psychiatry 2008;69(5):860-861

Article Abstract

Last month’s CORNER article examinedthe potential reasons and rationales for andconcerns about the combined use of antipsychotics.This article will review theevidence regarding the efficacy and safetyof antipsychotic polypharmacy in the treatmentof schizophrenia.

Buy PDF for $40.00

Please sign in or purchase this PDF for $40.00.

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 85 • 2024 • Number 4

Read the Current Issue

Meta-Analysis

Changes in Cognition in Patients With Schizophrenia

Systematic Review

Diagnostic Assessment via Telehealth vs Face-to-Face

Original Research

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Original Research

Bridge Symptoms Between Borderline Personality and PTSD

Original Research

Gepirone-ER and Sexual Function in Patients with MDD

Original Research

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

View current Issue

Related Articles

Best Practices for Switching to Clozapine in Patients With Schizophrenia

ASCP Corner

Best Practices for Switching to Clozapine in Patients With Schizophrenia

July 4, 2022

This article provides expert advice on dosage and timing when switching from a prior medication to clozapine in patients with schizophrenia.

Georgios Schoretsanitis, Jose de Leon

ASCP Corner

How to Make an Effective Offer of Clozapine

November 30, 2021

This ASCP Corner article discusses how to identify treatment-resistant patients who would benefit from clozapine and then offers tips on how to start the treatment conversation with these patients.

Jose M. Rubio, John M. Kane

ASCP Corner

Second-Generation Antipsychotics and Suicide

July 20, 2021

This ASCP Corner article reviews and clarifies the effects of second-generation antipsychotics on suicide, including both suicidal ideations and behaviors.

Zachary D. Zuschlag